Send to

Choose Destination
Evid Based Complement Alternat Med. 2019 Aug 29;2019:2509129. doi: 10.1155/2019/2509129. eCollection 2019.

Preclinical and Clinical Evidence Supporting Use of Cannabidiol in Psychiatry.

Author information

Department of Biomedical and Dental Sciences and Morphological and Functional Imaging, University of Messina, Messina, Italy.
Division of Pharmacognosy & Chemistry of Natural Products, Department of Pharmacy, University of Athens, Athens, Greece.
Anesthesia, Intensive Care and Pain Therapy, A.O.U. G. Martino Messina, University of Messina, Messina, Italy.
Research and Innovation Center in Phytotherapy and Integrated Medicine (CERFIT), Referring Center for Phytotherapy of Tuscany Region, Careggi University Hospital, Florence, Italy.
Psychiatry Unit, Department of Health Sciences, University of Florence, Florence, Italy.
Permanent Commission for Guidelines, Coordinator, Tuscany Region, Florence, Italy.



Cannabidiol (CBD) is a major chemical compound present in Cannabis sativa. CBD is a nonpsychotomimetic substance, and it is considered one of the most promising candidates for the treatment of psychiatric disorders.


The aim of this review is to illustrate the state of art about scientific research and the evidence of effectiveness of CBD in psychiatric patients.


This review collects the main scientific findings on the potential role of CBD in the psychiatric field, and results of clinical trials carried out on psychiatric patients are commented. A research was conducted in the PUBMED, SCOPUS, and ScienceDirect databases using combinations of the words cannabidiol, psychiatry, and neuropsychiatric.


Preclinical and clinical studies on potential role of CBD in psychiatry were collected and further discussed. We found four clinical studies describing the effects of CBD in psychiatric patients: two studies about schizophrenic patients and the other two studies carried out on CBD effects in patients affected by generalized social anxiety disorder (SAD).


Results from these studies are promising and suggest that CBD may have a role in the development of new therapeutic strategies in mental diseases, and they justify an in-depth commitment in this field. However, clinical evidence we show for CBD in psychiatric patients is instead still poor and limited to schizophrenia and anxiety, and it needs to be implemented with further studies carried out on psychiatric patients.

Conflict of interest statement

The authors declare that there are no conflicts of interest.

Publication type

Publication type

Supplemental Content

Full text links

Icon for Hindawi Limited Icon for PubMed Central
Loading ...
Support Center